Senator finds GSK profited by pulling children’ bronchial asthma inhaler

In 2024, medical doctors and oldsters scrambled to seek out an reasonably priced bronchial asthma inhaler after drugmaker GSK pulled the favored Flovent off the market. A senator launched an investigation to seek out out what occurred, sharing her findings completely with CNN. #information #cnn